← 返回

免疫治疗心脏毒性更新:检查点抑制剂、CAR-T 及其他

英文原题:Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.

查看英文原题

Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.

PubMed 2023/08/25(内容时间) Curr Treat Options Oncol Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫疗法是一种创新的癌症治疗方法,利用人体自身免疫系统对抗癌症。随着新疗法不断开发和优化,免疫疗法领域持续演进。最有前景的方式之一是免疫检查点抑制剂(ICI):这类药物靶向 T 细胞表面的蛋白质,解除对其攻击癌细胞能力的抑制,使 T 细胞能够更有效地识别和清除癌细胞。CAR-T 细胞疗法通过基因改造患者自身 T 细胞,使其识别并攻击癌细胞;该疗法对许多难治性血液系统恶性肿瘤患者具有良好缓解效果,针对实体瘤的临床试验也在不断增加。免疫调节药物则通过刺激免疫细胞生成或抑制免疫抑制细胞活性,增强免疫系统抗癌能力。尽管免疫疗法在癌症治疗中前景广阔,也可能造成显著心脏不良反应。ICI 等免疫治疗药物可引发心肌炎,导致胸痛、呼吸短促和心力衰竭;ICI 的其他心脏不良反应包括心律失常、心包炎、血管炎和加速性动脉粥样硬化。接受免疫疗法的患者应密切监测这些不良反应,及时治疗有助于预防严重并发症;患者也应立即向医务人员报告任何症状,以便采取适当措施。CAR-T 细胞疗法也可能诱发过度免疫反应,导致细胞因子释放综合征(CRS),并可能引发心血管事件,如心律失常、心肌梗死和心力衰竭。

总体而言,免疫调节疗法是具有前景且不断发展的癌症治疗方式,但应权衡潜在获益与风险和副作用,尤其要关注心血管并发症高风险患者。

展开英文摘要原文

Immunotherapy is an innovative approach to cancer treatment that involves using the body's immune system to fight cancer. The landscape of immunotherapy is constantly evolving, as new therapies are developed and refined. Some of the most promising approaches in immunotherapy include immune checkpoint inhibitors (ICIs): these drugs target proteins on the surface of T-cells that inhibit their ability to attack cancer cells. By blocking these proteins, checkpoint inhibitors allow T-cells to recognize and destroy cancer cells more effectively. CAR T-cell therapy: this therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells. CAR T-cell therapy exhibits favorable response in many patients with refractory hematological cancers with growing clinical trials in solid tumors. Immune system modulators: these drugs enhance the immune system's ability to fight cancer by stimulating the production of immune cells or inhibiting the activity of immune-suppressing cells.

While immunotherapy has shown great promise in the treatment of cancer, it can also pose significant cardiac side effects. Some immunotherapy drugs like ICIs can cause myocarditis, which can lead to chest pain, shortness of breath, and heart failure. Other cardiac side effects of ICIs include arrhythmias, pericarditis, vasculitis, and accelerated atherosclerosis.

It is important for patients receiving immunotherapy to be monitored closely for these side effects, as prompt treatment can help prevent serious complications. Patients should also report any symptoms to their healthcare providers right away, so that appropriate action can be taken. CAR T-cell therapy can also illicit an exaggerated immune response creating cytokine release syndrome (CRS) that may precipitate cardiovascular events: arrhythmias, myocardial infarction, and heart failure.

Overall, while immune modulating therapy is a promising and expanding approach to cancer treatment, it is important to weigh the potential benefits against the risks and side effects, especially in patients with high risk for cardiovascular complications.

论文信息

作者
Patel M、Hudson O、Han J、Kondapalli L、Arora G、Hawi R、Andrikopoulou E、Estes C
第一作者单位
University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.United Kingdom
通讯作者单位
University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA. clenneman@uabmc.edu.United Kingdom
文献类型
综述
期刊
Current treatment options in oncology2023 Nov
原文标识
PubMed 37624557 · DOI 10.1007/s11864-023-01130-y